Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | FAAH | O00519 | 3/20 | 0.51 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434698 | 1.00 | FASN (0.53) | FASNKDM4EFAAHSOAT1MEN1 | |
| SCHEMBL429605 | 0.85 | FASN (0.59) | FASNKDM4EFAAHCYP1A2CYP2C19 | |
| SCHEMBL429606 | 0.85 | FASN (0.59) | FASNKDM4EFAAHCYP1A2CYP2C19 | |
| SCHEMBL429511 | 0.84 | FAAH (0.49) | FASNKDM4EFAAHSOAT1MEN1 | |
| SCHEMBL429510 | 0.84 | FAAH (0.49) | FASNKDM4EFAAHSOAT1MEN1 | |
| SCHEMBL6473494 | 0.83 | FASN (0.56) | FASNKDM4EFAAHCYP1A2CYP2C19 | |
| SCHEMBL6473491 | 0.83 | FASN (0.56) | FASNKDM4EFAAHCYP1A2CYP2C19 | |
| SCHEMBL4437384 | 0.82 | ALDH1A1 (0.65) | FASNKDM4EFAAHSOAT1MEN1 | |
| SCHEMBL943538 | 0.82 | ALDH1A1 (0.65) | FASNKDM4EFAAHSOAT1MEN1 | |
| SCHEMBL5614117 | 0.82 | ALDH1A1 (0.65) | FASNKDM4EFAAHSOAT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507221-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals Inc. (CA) | 2012-10-10 | — | — | EP | disclosed |
| US-8101605-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS INC. (CA) | 2012-01-24 | — | — | US | disclosed |
| US-20110136802-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2011-06-09 | — | — | US | disclosed |
| WO-2011069118-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136802-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1D, PTPRO, PPM1G | FASN 4622/4885KDM4E 2971/4885FAAH 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.